BTIG Upgrades NeoGenomics to Buy, Announces $28 Price Target

Benzinga · 2d ago
BTIG analyst Mark Massaro upgrades NeoGenomics (NASDAQ:NEO) from Neutral to Buy and announces $28 price target.